The perspectives of physicians regarding antidiabetic therapy
de-intensification and factors affecting their treatment choices—A cross-sectional study

Abdallah Y. Naser1 | Zahra Alsairafi2 | Hassan Alwafi3,4 | Fawaz Mohammad Turkistani5 | Nedaa Saud Bokhari5 | Badi Alenazi6 | Eman Zmaily Dahmash1 | Hamad S. Alyami7

1Department of Applied Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan
2Department of Pharmacy Practice, Kuwait University, Kuwait, Kuwait
3Faculty of Medicine, Umm Alqura University, Mecca, Saudi Arabia
4Research Department of Practice and Policy, UCL School of Pharmacy, London, UK
5Al Noor Specialist hospital, Ministry of Health, Mecca, Saudi Arabia
6Paediatric Department, Alyamamah hospital, Riyadh, Saudi Arabia
7Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Saudi Arabia

Correspondence
Abdallah Y. Naser, Department of Applied Pharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman, Jordan.
Email: abdallah.naser@iu.edu.jo

Funding information
Najran University and Cancer Society in Najran

Abstract

Aims: Comprehensive diabetes management may include treatment intensification or the administration of antidiabetic combination therapy. However, this may be associated with an increased risk of adverse events and death. The aim of this study was to understand physicians’ perspectives regarding treatment de-intensification, HbA1c goals individualisation, and factors affecting their treatment choice for patients with type 2 diabetes mellitus (T2DM).

Methods: A cross-sectional study was conducted in primary and secondary care units in Saudi Arabia using online questionnaire. Two previously validated questionnaires were used to understand physicians’ awareness of, agreement with, and their practices of individualising HbA1c goals and antidiabetic treatment optimisation, and to assess factors affecting physicians’ treatment choice when prescribing antidiabetic treatment for patients with type 2 diabetes mellitus. Study population were physicians who are treating patients with diabetes mellitus during the period between October 2017 and May 2018.

Results: A total of 205 physicians have participated in the study. Approximately 50% of physicians had family medicine speciality (n = 98, 47.8%). The majority of physicians (n = 183, 89.3%) were familiar with the concept of HbA1c goals individualisation. However, only 66.3% of them (n = 136) reported that they apply it either always or most of the time. 58.5% (n = 120) of physicians reported that they would not initiate conversations about de-intensifying antidiabetic therapy even if their patients had a stable HbA1c values for one year. Physicians showed higher consideration to objective patient clinical data and their assessment of patient’s health status, with minor consideration to patient-related factors.

Conclusions: Healthcare professionals should focus more on implementing contemporary practices and applying any necessary treatment de-intensification or dose adjustment. Subjective patient factors should be taken into account further, as these factors are associated with better disease management.
The worldwide prevalence of diabetes mellitus (DM) in 2019, was 9.3%, while in Saudi Arabia a higher prevalence rate was reported (15.8%) putting an immense burden on the healthcare system. Direct expenses on diabetes in Saudi Arabia exceeded 13.9% of the total health expenditure. Unless a patient-centred, comprehensive multidisciplinary approach is enforced for the management of DM, the disease burden on Saudi Arabia will continue to escalate to an alarming level.

Comprehensive diabetes management includes an appropriate dietary plan, exercise, and antidiabetic medications. Nevertheless, the target glycaemic control is not always achieved using single antidiabetic medication and many patients may need to start treatment intensification to prevent the development of microvascular and macrovascular complications. Treatment intensification can be done either through increasing the dose of the single antidiabetic agent or by the administration of antidiabetic combination therapy.

Treatment guidelines recommend the use of intensive antidiabetic therapy for patients with uncontrolled DM. A previous large randomised controlled trial (RCT) reported that intensive antidiabetic therapy is associated with marked reduction in the risk of developing microvascular and macrovascular complications among type 2 diabetes mellitus patients (T2DM). Another large database study found that delay in treatment intensification is associated with multiple life-threatening complications such as myocardial infarction, stroke and heart failure. There are different variables that are reported to be associated with the need to treatment intensification in patients with DM such as high HbA1c value (8.0% and above), long duration of the disease and presence of other comorbidities. However, aggressive pharmacological treatment to achieve HbA1c targets may not be advisable or even practical and one size-fit all approach is not recently recommended. An enlightened patient-centred approach that determines individualised goals for each patient with ongoing follow up is recommended, however, weighting the risk and benefits is challenging. Intensive antidiabetic therapy should be used carefully as it is associated with an increased risk of adverse events and death. One of the leading adverse events associated with intensive antidiabetic therapy is hypoglycaemia. Hypoglycaemia has been a major concern for many researches recently, with some of the post-hoc analysis of RCTs have demonstrated an increased risk of death and cardiac complications with hypoglycaemia.

There are limited studies that addressed antidiabetic treatment de-intensification in order to decrease the clinical and economic burden of the associated hypoglycaemic episodes and to achieve the optimal HbA1c level. The excessive burden of DM, and the high prevalence of intensive antidiabetic therapy or as it is called “diabetes over-treatment,” increased the importance of exploring how physicians perceive this approach. This study aimed to understand physicians’ perspectives regarding anti-diabetic treatment de-intensification and factors affecting their treatment choices for patients with type 2 DM.

**What’s known**
- Treatment guidelines recommend the use of intensive antidiabetic therapy for patients with uncontrolled DM.
- Intensive antidiabetic therapy should be used carefully as it is associated with an increased risk of adverse events and death.
- Aggressive pharmacological treatment to achieve HbA1c targets may not be advisable or even practical and one size-fit all approach is not recently recommended.

**What’s new**
- Majority of physicians were familiar with the concept of HbA1c goals individualisation.
- Only 66.3% of physicians reported that they apply treatment de-intensification and dose adjustment in their practice.
- Physicians showed higher consideration to objective patient clinical data and their assessment of patient’s health status, with minor consideration to patient-related factors.

## 2 | METHODS

### 2.1 | Study design and study population

A cross-sectional survey study was conducted using two previously validated questionnaires. Genere and colleagues’ questionnaire, which was developed to understand physicians’ awareness of, agreement with and their practices of individualising HbA1c goals and antidiabetic treatment de-intensification. In addition, it has been used to identify HbA1c level at which physicians start treatment de-intensification and what important patient factors that motivate them to consider such practice. In addition, Grant and colleagues’ questionnaire, which was used to assess factors affecting physicians’ treatment choice when prescribing antidiabetic treatment for patients with type 2 DM has been used.

### 2.2 | Sampling and recruitment

Physicians from any related speciality, whether general practitioners, internists, or endocrinologists were invited to participate in the study. The inclusion criteria were any physician who currently practising his job and treating patients with type 2 DM.

A convenience sample of all eligible physicians who are registered in the Ministry of Health of Saudi Arabia was invited to participate in the study. Physicians were invited to participate in the study either by email or through sharing the online questionnaire link to them through social media websites such as twitter.
2.3 | Study instrument

Genere's questionnaire was developed by a panel of internal medicine physicians and specialist in health sciences research and diabetes affiliated with the National Institute of Health-funded Chicago Centre for Diabetes Transaction Research. The questionnaire has identified the concept of individualising HbA1c as “choosing an HbA1C goal for each patient based on their characteristics.” Physicians were asked whether they are familiar with this concept, using yes/no question format, and their agreement with this concept was measured using a 5-point Likert scale; ranged from strongly agree to strongly disagree. The frequency of the physician's practice of HbA1c goals individualisation was also measured using a 5-point Likert scale; ranged from always to rarely.

This was followed by asking physicians about their perspectives towards antidiabetic treatment de-intensification in terms of HbA1c goal and patients’ factors that they consider important to undertake this approach. Furthermore, physicians were asked about their gender, years of practice, country of medical education, percentage of patients aged 18 years and above and 65 years and above, percentage of patients with type 2 DM referring to their clinics and percentage of patients with diabetic complications.

The second questionnaire was Grant and colleagues’ questionnaire. It had been developed through conducting four focus groups with healthcare professionals including physicians working in primary care and diabetologists. In addition to factors identified based on the outcomes of the focus groups, Grant had also constructed his questionnaire based on previous literature. The questionnaire explored subjective patient factors (adherence behaviour, specific medication requests and patient's desire to delay or avoid insulin injection), physician related factors (physician's current or prior practice, size of practice, expert guidelines or hospital algorithms, physician's assessment of patient's health status and comorbid conditions), clinically measured patient data (age, weight, and last measured glycated haemoglobin [HbA1C]) and cost of antidiabetic medications chosen by the physician.

Physicians were asked to choose between three choices regarding the degree of importance of each variable (“major consideration,” “minor consideration,” or “not a consideration”).

2.4 | Ethical approval

Permission and approval for the use of the study questionnaires was sought from the corresponding authors. Participants were informed that by completing the online questionnaire, this would be considered written consent and agreement to participate in the study. The study has been approved by the Ministry of Health- Ethical Committee-Saudi Arabia.

2.5 | Statistical analysis

Data were analysed using the SPSS software, version 25. The descriptive analysis was reported as mean (μ) ± SD for normally distributed quantitative variables and as median (Interquartile range (IQR)) for non-normally distributed variables. Descriptive statistics was used to describe the respondents’ basic information. Categorical data were reported as percentages and frequencies. Logistic regression analysis and Chi-squared test were used to assess the relationship between physicians’ demographics and their awareness of, agreement with, and practice of HbA1c individualisation and antidiabetic treatment de-intensification. In addition, it was used to compare the response of physicians from different specialties. Physicians and practices covariates were dichotomised at the median (because of the skewness of the data), where years of experience were classified as equal to or more than 3 years and less than 3 years, size of practice as equal to or less than 1000 patients and more than 1000 patients, percentage of patients aged above 18 years or 65 years as equal to or less than 40% and more than 40%. A confidence interval of 95% (P < .05) was applied to represent the statistical significance of the results and the level of significance was assigned as 5%.

3 | RESULTS

3.1 | Physicians and practice characteristics

A total of 205 physicians have participated in this study. The majority of participants were males (n = 138, 67.3%) and approximately half of them had family medicine specialty (n = 98, 47.8%). The majority of physicians completed their medical education in Saudi Arabia (n = 136, 66.3%) with a median duration of 5.00 (IQR 3.00-10.00) years of practice. Around 88.8% (n = 182) of the physicians had an estimated monthly panel size of ≤500 patients. The vast majority of the physicians (n = 167, 81.8%) reported that more than 40% of their patients are aged 18 years and above, approximately half of physicians had patients with type 2 DM (n = 110, 53.6%) and a quarter of the sample (n = 55, 26.9%) had patients suffering from diabetic complications. Table 1 shows the details of physicians and practices characteristics.

3.2 | HbA1c goals individualisation

The majority of physicians (n = 183, 89.3%) reported that they were familiar with the concept of HbA1c goals individualisation. The vast majority (n = 170, 83%) of those who are familiar with the concept of HbA1c goals individualisation agreed with it. However, only 66.3% of them (n = 136) reported that they apply this concept in their daily practices most of the time or in all cases (Table 2).

Physicians' familiarity with the concept of HbA1c goals individualisation was significantly associated with their years of experience (OR: 1.07 (95% CI 1.01-1.13)) and percentage of T2DM patients with complications who visit their clinics (41-60%) (OR: 2.69 (95%CI 1.01-7.13). Physicians’ agreement with the concept of individualising HbA1c goals did not significantly differ between physicians from different demographics.
TABLE 1  Physicians and practice characteristics (n = 205)

| Category                                      | Number (%)          |
|-----------------------------------------------|---------------------|
| Gender                                        |                     |
| Female                                        | 67 (32.7)           |
| Male                                          | 138 (67.3)          |
| Speciality                                    |                     |
| Endocrinology                                 | 30 (14.6)           |
| Family medicine                               | 98 (47.8)           |
| Internal medicine                             | 32 (15.6)           |
| Paediatrics                                   | 6 (2.9)             |
| General practitioner                          | 39 (19.0)           |
| Country of medical education                  |                     |
| Local education                               | 136 (66.3)          |
| Europe                                        | 5 (2.4)             |
| Asia                                          | 41 (20.0)           |
| America                                       | 14 (6.8)            |
| Africa                                        | 8 (3.9)             |
| Australia                                     | 1 (0.5)             |
| Years of practice                             |                     |
| Median ± IQR (years)                          | 5.00 (3.00-1.00)    |
| 0-4 years                                     | 96 (46.8)           |
| 5-9 years                                     | 57 (27.8)           |
| 10-14 years                                   | 25 (12.2)           |
| 15-19 years                                   | 7 (3.4)             |
| 20-24 years                                   | 12 (5.9)            |
| ≥25 years                                     | 8 (3.9)             |
| Monthly size of patient panel                 |                     |
| 0-100 patient                                 | 67 (32.7)           |
| 101-250 patient                               | 68 (33.2)           |
| 251-500 patient                               | 47 (22.9)           |
| 501-1000 patient                              | 17 (8.3)            |
| 1001-1500 patient                             | 3 (1.5)             |
| >1500 patient                                 | 3 (1.5)             |
| % Patients >18 years old                      |                     |
| 0%-20%                                        | 21 (10.2)           |
| 21%-40%                                       | 17 (8.3)            |
| 41%-60%                                       | 37 (18.0)           |
| 61%-80%                                       | 61 (29.8)           |
| 81%-100%                                      | 69 (33.7)           |
| % Patients >65 years old                      |                     |
| 0%-20%                                        | 71 (34.6)           |
| 21%-40%                                       | 41 (20.0)           |
| 41%-60%                                       | 56 (27.3)           |
| 61%-80%                                       | 32 (15.6)           |
| 81%-100%                                      | 5 (2.4)             |
| % Patients with T2DM                         |                     |
| 0%-20%                                        | 40 (19.5)           |
| 21%-40%                                       | 55 (26.8)           |
| 41%-60%                                       | 47 (22.9)           |
| 61%-80%                                       | 48 (23.4)           |
| 81%-100%                                      | 15 (7.3)            |
| % Patients with T2DM and diabetic complications|                     |
| 0%-20%                                        | 89 (43.3)           |
| 21%-40%                                       | 61 (29.8)           |
| 41%-60%                                       | 35 (17.1)           |
| 61%-80%                                       | 17 (8.3)            |
| 81%-100%                                      | 3 (1.5)             |
3.3 | Diabetes therapy de-intensification

More than half of the participated physicians (58.5%; n = 120) reported that they do not initiate conversations with their patients about discontinuing or reducing the dose of their medications even if they had a stable HbA1c values for one year. Some physicians (n = 48, 23.5%) used a predefined HbA1c values as a cut-off point to initiate conversations about de-intensifying the diabetes therapy dose or regimen. Only 8.3% (n = 17) of physicians used individualised HbA1c levels to initiate this conversation. Different predefined HbA1c levels were used by physicians to initiate conversations on antidiabetic therapy de-intensification. In addition, 19% (n = 39) of physicians used HbA1c levels that ranged between 6.0% and 7.0%, as a predefined HbA1c levels. The three most important clinical situations in which the physicians initiate a conversation about antidiabetic therapy de-intensification were: if the patient has experienced symptoms that could be related to their medications (22.4%, n = 46), the patient is at risk for polypharmacy (15.1%, n = 31), or showed non-adherence to medications or having concerns about the cost of their medications (8.8%, n = 18) (Table 3). Initiating a conversation about antidiabetic therapy de-intensification was associated (OR: 2.14 (95%CI 1.10-4.17)) with percentage of patients aged 18 years and above who visit physicians’ clinics (81-100%).

3.4 | Physicians consideration of antidiabetic medication choice

When selecting the antidiabetic therapy for patients, physicians showed a higher consideration to last measured HbA1c level (94.9%, n = 168), comorbid conditions co-existed with diabetes (93.8%, n = 166), their assessment of patient’s health status (88.1%, n = 156). However, physicians showed a minor consideration to subjective patient factors such as specific medication requests by the patient (53.1%, n = 94), physician’s current or prior practice (43.5%, n = 77) and medication costs (44.6%, n = 79) (Figure 1).

4 | DISCUSSION

This study showed that majority of the participating physicians were familiar with the concept of individualising HbA1c goals for patients with DM, and the majority agreed with the concept and apply it in their daily practices. Nevertheless, only 34.6% (n = 71) declared that they would initiate a conversation to de-intensify diabetes therapy with their patients if they were stable for one year which could put the patients under the risk of unnecessary over treatment and polypharmacy. Regarding the factors that mostly considered by physicians when prescribing antidiabetic medications, patients’ comorbidity, patients’ health status and last measured HbA1c level were the most considered factors. Such a trend is alarming as recent studies revealed an increased risk of admission for hypoglycaemia in DM patients aged ≥50 years. Hypoglycaemia is a key risk of intensive pharmacological treatment with antidiabetic drugs. However, de-intensification trends vary, wherein one study, general practitioners reported that they do not initiate treatment in older patients because of potential hypoglycaemia and prescribe the antidiabetic drug only when HbA1c levels exceeded recommended values. Another previous retrospective study involving 3186 patients, reported that the de-intensification of treatment options is uncommon for older patients with DM, The new classes of antidiabetic medications that have low risk of hypoglycaemia should be recommended, and the use of sulfonylureas or insulin should be discouraged in type 2 diabetic patients, particularly in older patients. However, sometimes insulin is indispensable to ameliorate the glycaemic control or when patient’s clinical comorbidities do not allow other medications. Insulin therapy de-intensification should be guided by the presence of hypoglycaemia, the resolution of particular clinical situations (such as infections,
surgery, and hospitalisations), the intensification of lifestyle management and the HbA1c as well.

Although healthcare guidelines recommend treatment individualisation,8,9 a considerable proportion of physicians (9.3%) stated that they were not familiar with the concept of HbA1c goals individualisation despite that the majority of patients they treat are above 65 years. Unawareness about this concept might increase the risk of "over-treatment" of patients with type 2 DM, which may cause additional harm and cause adverse drug reactions such as hypoglycaemia particularly for the elderly.32-34 Many factors could be associated with diabetes overtreatment by healthcare professionals such as being unaware of individualising treatment target.35 Physicians' familiarity with the concept of HbA1c goals individualisation was significantly associated with physicians' years of experience and

### TABLE 3  Physicians' perspectives and practices of antidiabetic therapy de-intensification

| Question                                                                 | Yes  (Number | %) | No  (Number | %) | Missing data (Number | %) |
|--------------------------------------------------------------------------|------------|----|------------|----|---------------------|----|
| "In general, if your patient with type 2 diabetes has a stable HbA1c level for 1 year, do you ever initiate conversations about discontinuing or reducing the dose of their diabetes medications? (n = 191)" | 71 (34.6) | 120 (58.5) | 14 (6.8) |
| "At what HbA1c level do you initiate this conversation? (n = 71)" | <5.0% | 3 (4.2) | <5.7% | 4 (5.6) | <6.0% | 15 (21.1) | <6.5% | 13 (18.3) | <7.0% | 11 (15.5) | <8.0% | 2 (2.8) | Depends on patient characteristics | 17 (24) | Missing data | 6 (8.5) |
| "In what other clinical situations do you initiate this conversation? (n = 71)" | When a patient has symptoms that could be from their medications | 46 (64.8) | When a patient is at risk for polypharmacy | 31 (43.7) | When a patient raises concerns about the costs of medications | 18 (25.4) | When a patient may not be taking the medicine as prescribed | 18 (25.4) | When a patient is diagnosed with a condition that significantly reduces their life expectancy | 17 (23.9) |

---

**FIGURE 1  Physicians considerations when prescribing antidiabetic medications (n = 205)**

![Bar chart showing various factors considered by physicians when prescribing antidiabetic medications.](chart.png)
percentage of T2DM patients with complications who visit their clinics. Physicians’ agreement with the concept of individualising HbA1c goals did not significantly differ between physicians from different demographics. Unlike a previous study, which showed that female physicians had a higher possibility of initiating such conversations with their patients, we found that male physicians showed a higher possibility of initiating conversations about antidiabetic therapy de-intensification compared with females. Previous studies showed that male physicians usually have shorter durations of consultations with their patients than female physicians, ask them less questions, and do not discuss physical activities and lifestyle with them. The process of initiating antidiabetic therapy adjustment conversations is restricted by the limited time spent in clinical practice during the provision of healthcare to patients, as such conversation requires a thorough discussion of the risks and benefits related to antidiabetic therapy de-intensification.

In this study, almost one third (34.6%) of the physicians reported that they would initiate a conversation about antidiabetic therapy de-intensification with patients who maintained stable for one year. Pre-defined HbA1c levels were used by many physicians as a cut-off point to initiate their discussions about antidiabetic therapy de-intensification, with 30.9% of them using HbA1c levels that ranged from 6% and lower. Only 24% of the participating physicians reported that such discussions depend on patient’s characteristics. However, variations in the HbA1c level being considered by physicians reflects the differences in physicians’ awareness about guideline recommendations and their uncertainty on how and when to adjust or de-intensify antidiabetic therapy. Such physicians’ unawareness may increase the risk of experiencing adverse events by patients because of over-treatment. Some patients, such as those with cardiovascular diseases could be at a higher risk of antidiabetic therapy over-treatment, and their physicians should consider antidiabetic therapy adjustment at an earlier stage. Some studies suggested the added value of de-intensification that outweighs the harm, particularly in older patients. However, to date, there is no solid established strategies on how to implement antidiabetic therapy de-intensification to prevent the harm of overtreatment.

The current study found that physicians have various considerations when prescribing antidiabetic therapy for their patients. The majority of physicians highly considered patients’ comorbidity, patients’ health status and last measured HbA1c level. Majority of physicians also reported that they do not consider patient subjective factors such as specific medication request and medication cost. Healthcare professionals should employ a patient-centred approach that considers patient subjective factors, physician related factors, clinically measured patient data, and medications costs as all of these factors are associated with better disease management. The provision of care for diabetic patients in Saudi Arabia is not limited to specialised physicians, it can be provided across the spectrum of healthcare including primary healthcare facilities that provide services to non-communicable diseases, which include diabetes. For this reason, guideline bodies need to set recommendations for approaches to de-intensify treatment options for DM patients that cater to the diversity of the disease itself as well as the healthcare providers. Nowadays, diabetologists prescribe particular classes of antidiabetic medications (such as glucagon-like peptide-1 receptor agonists (GLP1ra) or sodium-glucose cotransporter-2 inhibitors (SGLT2i)) not only to achieve the glycaemic target, but in order to reach cardiovascular protection or weight loss. Because of this, the reduction of HbA1c (or its stability) should not be the only valid reason to stop a drug that could modify patients’ clinical history. On the contrary, a complication (such as myocardial infarction) could push the doctor to add a medication also in presence of a perfect glycaemic control. At the same time, physicians should provide further education to their patients on how to self-manage their hypoglycaemic events, as majority of these events are of mild to moderate severity and do not need hospitalisation. A previous study in Jordan highlighted that patients with diabetes mellitus have moderate problem-solving ability towards their hypoglycaemic events, specifically, physicians need to emphasise in their education on the overall problem-solving perception of hypoglycaemia and its immediate management.

This study has several strengths, it is the first study to be conducted in Saudi Arabia exploring physicians’ perspectives towards antidiabetic therapy de-intensification, and factors affecting their treatment choice. Also, this study included physicians from different specialties, which ensured the generalisability of the findings. In addition, recruiting participants using different methods, for example, social media and email ensured the good response rate. On the other hand, this study has some limitations. The responses could be prone to a social desirability bias because some physicians may not wish to show their unawareness about healthcare recommendations and guidelines regarding the need for treatment de-intensification. However, we expect that this is minimal, since around 9.3% of the participants reported that they are not familiar with such concept. In addition, the use of the questionnaire in this study could limit the options to the physicians in some aspects and restrict their answers to what were already identified, for example, the subjective patient factors that affect the physicians’ choice of treatment.

This research addressed the “over-treatment” problem among patients with type 2 diabetes in the country. The study has also revealed the attitudes and perspectives of physicians towards treatment de-intensification and dose adjustment. This would help policy makers to interpret the importance of such issue and propose guidelines for the management of type 2 diabetes in the region, particularly addressing the importance of treatment optimisation. In addition, this would help in reducing adverse events and mortality rates in this group of patients, and improve the economic and health outcomes.

Physicians should educate their patients after implementing this approach to monitor their blood glucose levels on a continuous basis to have a better control, and to decrease the probability of experiencing any potential drug adverse events. Continuous education programmes to healthcare professionals should focus more on updating physicians’ knowledge about contemporary practices and highlight the importance of revising patients’ therapy on continuous
basis to implement any necessary treatment de-intensification. This would decrease the possibility of unintended overtreatment of patients that might increase their potential harm because of adverse drug events.

As there is a scarcity of studies examining physicians’ perspectives regarding treatment de-intensification in type 2 diabetes in the Middle East, it will be interesting to conduct more studies using different methods eg, interviews or focus groups. This will ensure the exploration of all factors that could affect the perspectives of physicians regarding this issue, and hence, drawing a broader picture about the management of such growing disease in the area. This will assist in designing the appropriate protocols and guidelines for the management of type 2 diabetes.

5 | CONCLUSIONS

The findings of this study showed that antidiabetic therapy adjustment and follow up is under practice among physicians in Saudi Arabia. Physicians should use a cut-off point for initiating conversations about diabetes therapy choices and dose adjustment based on patients’ clinical profile and tailored to their health status. Antidiabetic therapy de-intensification approach should only be approached if the patients experienced unwanted side effects and specifically hypoglycaemia.

ACKNOWLEDGEMENTS

This study was supported by Isra University (Amman, Jordan) and Najran University and Cancer Society in Najran, Saudi Arabia.

DISCLOSURES

The authors declare that they have no competing interests.

ORCID

Abdallah Y. Naser https://orcid.org/0000-0001-8440-7446

REFERENCES

1. International Diabetes Federation (IDF). Diabetes Atlas. 9th edition. Brussels: Brussels International Diabetes Federation; 2019:1–2.
2. Robert A, Al Dawish M, Braham R, Musallam M, Al Hayek A, Al Kahtany N. Type 2 diabetes mellitus in Saudi Arabia: major challenges and possible solutions. Curr diabet Rev. 2017;13:59-64.
3. Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabet. 1997;46:S101-S103.
4. Riedel AA, Heien H, Wogen J, Plauschint CA. Loss of glycemisc control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharma. 2007;27:1102-1110.
5. Turner RCC, Frichti V, Holman R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. J Am Med Assoc. 1999;281:2005-2012.
6. Lavernia F, Adkins SE, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goals. Postgrad Med J. 2015;127:808-817.
7. ADA. ADA. Standards of medical care in diabetes. Diab Care. 2016;39:S39–45.
8. (NICE). NIfHaCE. Type 1 diabetes in adults: diagnosis and management. 2015. https://pathways.nice.org.uk/pathways/type-1-diabetes-in-adults/#path=view%3Apathways/type-1-diabetes-in-adults/insulin-therapy-for-adults-with-type-1-diabetes.xml&content=view-index. Accessed April 01, 2017.
9. (NICE). NIfHaCE. Type 2 diabetes in adults: management. 2015. https://www.nice.org.uk/guidance/ng28/chapter/1-recommendations. Accessed March 15, 2018.
10. (NICE). NIfHaCE. Managing blood glucose in adults with type 2 diabetes. 2016. https://pathways.nice.org.uk/pathways/type-2-diabetes-in-adults/managing-blood-glucose-in-adults-with-type-2-diabetes.xml&content=view-node%3Anodes-drug-treatment. Accessed January 25, 2018.
11. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Eng J Med. 2008;358:2560-2572.
12. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diab. 2015;14:1-10.
13. Mata-Cases MF-NJ, Real J, Gratacos M, Lopez-Simarro F, Khunti K, Mauricio D. Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment. Diab Obes Metab. 2018;20:103-112.
14. Inzucchi SE, Bergenstrahl RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes 2015: a patient-centered approach. Diab Care. 2015;38:140-149.
15. Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Hear Assoc. 2015;4:1-18.
16. Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174:1116-1124.
17. Naser AY, Wong ICK, Whittlesea C, et al. Use of multiple antidiabetic medications in patients with diabetes and its association with hypoglycaemic events: a case-crossover study in Jordan. BMJ Open. 2018;1-8.
18. Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrin. 2016;12:222-232.
19. Davis TM, Brown SG, Jacobs IG, Bulsara M, Bruce DG, Davis WA. Determinants of severe hypoglycaemia complicating type 2 diabetes: the Fremantle diabetes study. J Clin Endocrinol Metab. 2010;95:2240-2247.
20. Mellbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart. 2009;95:721-727.
21. Berkowitz SA, Aragon K, Hines J, Seligman H, Lee S, Sarkar U. Do clinical standards for diabetes care address excess risk for hypoglycaemia in vulnerable patients? A systematic review. Health Serv Res. 2013;48:1299-1310.
22. Naser AY, Alwafi H, Alsairafi Z. Cost of hospitalisation and length of stay due to hypoglycaemia in patients with diabetes mellitus: a cross-sectional study. Pharm Pract. 2020;18:1847.
23. Genere N, Sargs RM, Masi CM, et al. Physician perspectives on de-intensifying diabetes medications. Med. 2016;95:e5388.
24. Collins D. Pretesting survey instruments: an overview of cognitive methods. Qual Life Res. 2003;12:229-238.
25. Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes: a national survey of specialists and academic generalists. Diab Care. 2007;30:1448-1453.
26. Farmer A, Kinmonth A-L, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabetic med. 2006;23:265-270.
27. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U. S. academic medical centers: low rates of medical regimen change. Diab Car. 2005;28:337-442.
28. Spoelstra JAKO, Erkens JA, Rutten EG, Leufkens HG, Grobbee DE. Initiation of glucose-lowering therapy in type 2 diabetes mellitus patients in general practice. Diab Med. 2008;2:896-900.
29. Zaccardi F, Davies MJ, Dhalwani NN, et al. Trends in hospital admissions for hypoglycaemia in England: a retrospective, observational study. Lancet Diabet Endocrin. 2016;4:677-685.
30. Zhang Q, Marrett E, Jameson K, et al. Reasons given by general practitioners for non-treatment decisions in younger and older patients with newly diagnosed type 2 diabetes mellitus in the United Kingdom: a survey study. BMC Endocrin Dis. 2011;11:17.
31. Daniela VP, Rajesh G. De-intensification of diabetes treatment in elderly patients with type 2 diabetes mellitus. Endocrin Pract. 2019;25:1317-1322.
32. Gerstein HMM, Gennuth S, Ismail-Beigi F, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. New Eng J Med. 2011;364:818-828.
33. Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glyemic control. JAMA Intern Med. 2015;175:356-362.
34. Tseng C-L, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at high risk of hypoglycemic risk. JAMA Intern Med. 2014;174:259-268.
35. Feil DG, Rajan M, Soroka O, Tseng C-L, Miller DR, Pogach LM. Risk of hypoglycemia in older veterans with dementia and cognitive impairment: Implications for practice and policy. J Am Ger Soc. 2011;59:2263-2272.
36. Hall JA, Irish JT, Roter DL, Ehrlich CM, Miller LH. Gender in medical encounters: an analysis of physician and patient communication in a primary care setting. Health Psych. 1994;13:384-392.
37. Jefferson L, Bloor K, Hewitt C. The effect of physician gender on length of patient consultations: observational findings from the UK hospital setting and synthesis with existing studies. J Royal Soc Med. 2015;108:136-141.
38. Ramirez A, Wildes K, Napoles-Springer A, Perez-Stable E, Talavera G, Rios E. Physician gender differences in general and cancer-specific prevention attitudes and practices. J Can Educat. 2009;24:85-93.
39. Tabenkin H, Eaton CB, Roberts MB, Parker DR, McMurray JH, Borkan J. Differences in cardiovascular disease risk factor management in primary care by sex of physician and patient. Annu Fam Med. 2010;8:25-32.
40. Tabenkin H, Goodwin MA, Zyzanski SJ, Stange KC, Medalie JH. Gender differences in time spent during direct observation of doctor-patient encounters. J Wom Health. 2004;13:341-349.
41. Laiteerapong N, John PM, Nathan AG, Huang ES. Public health implications of recommendations to individualize glycemic targets in adults with diabetes. Diab Car. 2013;36:84-89.
42. Seidu SKS, Topsever P, Hambling CE, Cos FX, Khunti K. Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes. Diabet Obes Metab. 2019;21:1668-1679.
43. Al-Rubeaan K, Al-Manaa H, Khoja T, et al. Health care services provided to type 1 and type 2 diabetic patients in Saudi Arabia. SPJ. 2015;36:1216-1225.
44. Naser AY, Wong ICK, Whittlesea C, et al. Attitudes and perceptions towards hypoglycaemia in patients with diabetes mellitus: a multinational cross-sectional study. PLoS ONE. 2019;14:e0222275.

How to cite this article: Naser AY, Alsairafi Z, Alwafi H, et al. The perspectives of physicians regarding antidiabetic therapy de-intensification and factors affecting their treatment choices—A cross-sectional study. Int J Clin Pract. 2021;75:e13662. https://doi.org/10.1111/ijcp.13662